MedPage Today (3/18, Monaco) reports a study published in JAMA Psychiatry found that “psilocybin plus psychotherapy showed limited efficacy for easing depressive symptoms in individuals with treatment-resistant depression.” According to researchers, “after withdrawal from antidepressants, 17% and 12.5% of patients who received one dose of 25 mg and 5 mg psilocybin, respectively, achieved at least a 50% reduction in Hamilton Rating Scale for Depression-17 (HAMD17) at week 6 compared with 10.6% of controls who received placebo in the form of nicotinamide.” They noted that “for 25 mg psilocybin vs nicotinamide, the adjusted was OR 1.73. Because the first hierarchical comparison was nonsignificant, no further formal testing was performed.” Furthermore, a systematic review and meta-analysis, also published in JAMA Psychiatry, concluded that “psychedelic-assisted therapy was no more effective than open-label treatment with traditional antidepressants.”
Related Links:
— MedPage Today (requires login and subscription)